Firm Resume
Transkaryotic Therapies Securities Litigation
Transkaryotic Therapies Securities Litigation was a securities fraud case brought on behalf of a class of purchasers of company stock, alleging misrepresentations about correspondence from the FDA with respect to prospects for approval of one of the company’s key products. The case was settled for a cash fund of $50 million.